Fosamprenavir and Indinavir

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with indinavir may increase the plasma concentrations of amprenavir. The mechanism is indinavir inhibition of amprenavir metabolism via CYP450 3A4. In 9 study subjects, indinavir (800 mg three times a day for 2 weeks) increased the peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and trough plasma concentration (Cmin) of amprenavir (750 or 800 mg three times a day for 2 weeks) by 18%, 33% and 25%, respectively, compared to administration of amprenavir alone. The clinical significance of these changes is unknown. Patients receiving amprenavir or fosamprenavir with indinavir should be monitored for potentially increased side effects of both drugs. Appropriate dosages of the drugs in combination with respect to safety and efficacy have not been established.

Fosamprenavir

Generic Name: fosamprenavir

Brand name: Lexiva, Telzir

Synonyms: n.a.

What is Fosamprenavir?

Indinavir

Generic Name: indinavir

Brand name: Crixivan

Synonyms: n.a.

What is Indinavir?